

**COMPLETE LISTING OF CLAIMS**

Please amend claim 4, without prejudice or admission, so that the pending claims will be as shown in the following complete listing of all claims ever presented for this application (37 C.F.R. 1.121(c)):

1. (Original) A method of treating patients who have diseases characterized bone loss comprising the step of administering to said patient an amount of TRANCE/RANK inhibitors effective to inhibit osteoclastogenesis and/or osteoclast function.
2. (Original) The method of claim 1 wherein said TRANCE/RANK inhibitor is a compound having the Formula I wherein:

R<sub>1</sub>, and R<sub>2</sub> are, independently, selected from the group consisting of -H, - OCH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -*t*-butyl, 3-carboxy-4-chlorophenylamino, -N-(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, and - O(O)C-Ph;

R<sub>3</sub> is selected from the group consisting of -H, ethyl, -OCH<sub>3</sub>, -Cl, Br, F, 3carboxy-4-chlorophenylamino, -N-(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -*t*-butyl, and -OC(O)-Ph, and is not limited to attachment at any certain position on the phenyl ring to which it is attached; and

R<sub>4</sub> is selected from the group consisting of -Br,-Cl, and -F.

3. (Original) The method of claim 2 wherein R<sub>3</sub> is attached at either the 1 or 4 position of the 15 phenyl ring.
4. (Currently amended) The method of claim 1 wherein said TRANCE/RANK inhibitor is a compound having the Formula I wherein:

R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are -OCH<sub>3</sub>, R<sub>3</sub> is attached at the 4 position, R<sub>4</sub> is -Cl;

R<sub>1</sub>, and R<sub>2</sub> are methyl, R<sub>3</sub> is ethyl, attached at the 4 position, R<sub>4</sub> is -Cl;

R<sub>1</sub>, and R<sub>2</sub> are -OCH<sub>3</sub>, R<sub>3</sub> is -Cl, attached at the 2 position, R<sub>4</sub> is -Cl;

R<sub>1</sub>, and R<sub>2</sub> are -OCH<sub>3</sub> and R<sub>3</sub> is H, R<sub>4</sub> is -Cl;

R<sub>1</sub>, is H, R<sub>2</sub> and R<sub>3</sub> are 3-carboxy-4-chlorophenylamino, and R<sub>3</sub> is attached at the 4 position, R<sub>4</sub> is -Cl;

R<sub>1</sub> and R<sub>2</sub> are -N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, R<sub>3</sub> is Cl, attached at the 4 position, R<sub>4</sub> is -Cl;

R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are *t*-butyl, R<sub>3</sub> is attached at the 4 position, R<sub>4</sub> is -Cl;

R<sub>1</sub>, is -OCH<sub>3</sub>, R<sub>2</sub> and R<sub>3</sub> are H, R<sub>4</sub> is Cl; or

R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are benzoate, R<sub>3</sub> is attached at the 4 position, R<sub>4</sub> is Br.

5. (Original) The method of claim 1 wherein said TRANCE/RANK inhibitor is selected from the group consisting I-A, I-B, I-C, I-D, I-E, I-F, I-G, I-H and I-I.

6. (Original) The method of claim 1 wherein said TRANCE/RANK inhibitor is a compound having the Formula II wherein:

R<sub>1</sub> is selected from the group consisting of -diphenylchloro methyl, -di(4chlorophenyl)chloro methyl, and 4-(diphenylchloromethyl)phenyl; and R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> are independently selected from the group consisting of -Br, -Cl, and -F.

7. (Original) The method of claim 6 wherein R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> are each -Cl.

8. (Original) The method of claim 1 wherein the TRANCEIRANK inhibitor is selected from the group consisting compounds II-A, II-B, II-C and II-D.
9. (Original) The method of claim 1 wherein said inhibitor is a compound having Formula III wherein:

$R_1 = (NO_2)_2, O(CO)CH_3, OH, O(CO)CH_3,$   
 $O(CO)(CH_2)_2COOH, O(CO)CH_2Br, O(CO)CH_2Cl,$   
 $O(CO)CH_2N(CH_3)_3, \text{ or } OC_5H_9O; R_2 = CH_2O(NO_2), CHO,$   
 $CH_2O(NO_2), CN, CH_3, COOH, CHNOH,$   
 $CH_2O(CO)(CH_2)_2COOH, CHN(NH)CONH_2, CHN(NH)C_6H_5,$   
 $CHN(CH_2)C_6H_5, CH_2N(CH_2)_2OH, CH_2NC_6H_5, \text{ or }$   
 $CH_2N(NH)CSNH_2;$

$R_3 = OH, \text{ or } H;$

$R_4 = CH_3;$

$R_5 = OH;$

$R_6 = C_4H_9O_2, N(NHCO)C_6H_4Cl, N(NHCO)C_6H_4F, COOH, O,$   
 $COCH_3, CH(CH_3)(CH_2)_2COOH, CH(CH_3)(CH_2)_2COOCH_3,$   
 $O(CO)C_6H_5, \text{ or } OH;$


$R_7 = O(CO)CH_2N(CH_3)_3, \text{ or } O(CO)CH_3;$

$R_8 = OH;$




$R_9 = O, \text{ or } OH; \text{ and } R_{10} = O$

$R_{10} = O.$



10. (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds III-1 to III-31.
11. (Original) The method of claim 1 wherein said inhibitor is a compound having Formula IV wherein:



12. (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds IV-1 and IV-2.
13. (Original) The method of claim 1 wherein said inhibitor is a compound having Formula V wherein:



14. (Original) The method of claim 1 wherein the inhibitor is selected from the group consisting compounds V-1 and V-5
15. (Original) The method of claim 1 wherein said inhibitor is a compound having Formula VI wherein:



$R_3 = O, \text{ or } OH;$

$R_4 = CH_3;$

$R_5 = C_9H_{13}COCH_3, C_9H_{13}(CH_2CH_3)(CH_2OH),$   
 $C_9H_{13}(CH_2CH_3)(CH_2OCH_3), C_9H_{13}(CH_2CH_3)(CH_2$   
 $OCO(CH_2)_2COOH), C_9H_{13}(CH_2CH_3)(COOH), \text{ or}$   
 $C_8H_7O(CH_3)(C_4H_9OCH_3);$

$R_6 = CH_3;$

$R_7 = O, \text{ or } H;$

$R_8 = CH_3;$

$R_9 = (CH_3)_2; \text{ and}$

$R_{10} = Br.$

16. (Original) The method of claim I wherein the inhibitor is selected from the group consisting compounds VI-1 and VI-11.
17. (Original) The method of claim I wherein the inhibitor is selected from the group consisting compounds VII, VIII IX, X, XI and XII.

Claims 18-43: (Cancelled)

\* \* \* \* \*